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Purpose: The present study aims to investigate the effect of the group-based Proactive 
Interdisciplinary Self-Management (PRISMA) training program on medication adherence in 
patients with type 2 diabetes (T2DM) treated in primary care.
Patients and methods: The current study is a two-arm, parallel group, randomized, open 
label trial (1:1) of 6-month duration with a 6-month extension period in which both groups 
received the intervention (wait-list control). People 18 years old or older who were diagnosed 
with T2DM were included. The intervention consisted of two group meetings about T2DM 
guided by care providers. The control group received usual care only (visits at the general 
practice). The primary outcome was adherence based on pharmacy refill data and was measured 
using medication possession ratio (MPR). The secondary outcomes were the number of drug 
holidays and self-reported adherence, measured by the 5-item Medication Adherence Rating 
Scale (MARS-5).
Results: Of the total sample (n=108), 66.6% were male. The mean age was 69.3 years (SD=9.1). 
In the 6-month period, patients were more adherent in the intervention group (n=56) (median 
MPR =100.0 [51.1–100.0]) than in the control group (n=52) (median MPR =97.7 [54.1–100.0]) 
(U=1,042, z=-2.783, P=0.005). The intervention group had less drug holidays than the control 
group (relative risk 0.55, 95% CI, 0.37–0.80). The sum scores of the MARS did not differ between 
the intervention group (median =23.98, SD=0.91) and the control group (median =24.00, SD=1.54).
Conclusion: The PRISMA program resulted in a small improvement in MPR and fewer drug 
holidays, while no improvement has been found in self-reported adherence. However, health 
care providers and policy makers could take into account that adherence might be influenced 
by PRISMA.
Keywords: MPR, refill data, drug holidays, MARS, group education
Introduction
Type 2 diabetes mellitus (T2DM) is a highly prevalent, predominantly lifestyle-related, 
chronic condition.1 In the Netherlands, 51 per 1,000 persons are affected by T2DM. 
This rate is expected to increase to 80 per 1,000 persons in 2025,2 especially – but not 
exclusively – among those with unhealthy lifestyles.3 T2DM is related to an increased 
risk of developing macro- and microvascular complications, including cardiovascular 
disease, diabetic retinopathy, neuropathy, and nephropathy.1
In the Netherlands, T2DM is mainly treated in primary care by the general prac-
titioners (GPs) and the primary care practice nurse (PN). For patients with T2DM, 
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restoring a healthy lifestyle is the cornerstone of treatment. 
Self-management is challenging, because the combination 
of adequate knowledge, skills, perseverance, and motiva-
tion to initiate and maintain behaviors that can help manage 
the disease on a daily basis is difficult for many patients to 
achieve.4 Influential self-management behaviors involve a 
healthier diet, more physical activity, self-monitoring of 
blood glucose levels when needed, and taking medication 
according to prescription.5
Most patients with T2DM additionally need to be treated 
with glucose-lowering medication (oral blood glucose–low-
ering medication, eventually followed by insulin). In 2014, in 
the Netherlands, 800,000 patients were treated with glucose-
lowering medication, and 82% of T2DM patients took their 
medication as prescribed.6 Medication adherence has been 
defined by the World Health Organization as the extent to 
which a person’s medication taking behavior corresponds 
with agreed recommendations from a health care provider 
(HCP).7 Although medication adherence is a crucial factor in 
the effectiveness of a therapy, it is a complex behavior with 
several aspects,8 which makes it difficult to measure.9 Medi-
cation adherence can be divided into three interrelated yet 
distinct phases: the initiation of the treatment, the implemen-
tation of the prescribed regime, and the discontinuation of 
the pharmacotherapy. Medication non-adherence can occur 
in any of these phases.10 Non-adherence can be considered as 
a significant health care problem, especially for patients with 
chronic illnesses.11 In T2DM, glycemic (the levels of blood 
glucose) control is essential to prevent long-term macro- and 
microvascular complications.
One way to encourage self-management and lifestyle 
change is through group-based diabetes self-management 
education.12,13 Group-based education possesses the advan-
tages of having patient meetings, discussions, and peer 
motivation.12 Furthermore, group-based education has been 
found to result in improvements in clinical, lifestyle, and 
psychosocial outcomes.14 In the Netherlands, the group-based 
Proactive Interdisciplinary Self-Management (PRISMA) 
training program was developed. It was adapted from the 
Diabetes Education and Self-Management for Ongoing 
and Newly Diagnosed (DESMOND) program developed 
in the UK for primary diabetes care.15–17 DESMOND was 
translated into Dutch and adapted to the Dutch health care 
system. With PRISMA, patients are challenged to consider 
their own personal risk factors and to choose a specific goal 
of behavior change.18 In the PRISMA sessions, the risk fac-
tors for T2DM were discussed, as well as the expected effect 
of insulin or oral blood glucose–lowering medication on 
blood glucose levels. In addition, patients were challenged 
to formulate their own personal risk factors and to choose 
a specific goal of behavior change, for example, “taking 
medication as prescribed.” A better understanding of the 
ways that “medications” can affect T2DM could stimulate 
patients to be adherent to their medication therapy.
Moreover, because adherence is an important aspect 
of self-management, a change in medication intake due to 
PRISMA can be hypothesized. Unfortunately, little is known 
about the actual effect of these kinds of self-management 
education programs on medication adherence in patients with 
T2DM.19 The present study aims to investigate the effect of 
PRISMA on medication adherence in patients with T2DM 
treated in primary care.
Patients and methods
Trial design
The current study is part of the Diabetes Education and Self-
Management to Increase Empowerment (DESTINE) study, 
described in detail elsewhere.20
The current study was performed with data available 
from DESTINE.20 A power calculation was carried out on 
the primary outcome measure (platform use), and therefore 
a sample size calculation was not performed for examining 
effects on adherence in the present study.
DESTINE is a two-arm, parallel group, randomized, open 
label trial (1:1) conducted over a period of 6 months. The 
study investigated sustainability in the intervention group 
during a 6-month extension period (wait-list control), in 
which both groups received the intervention. The control 
group received the intervention as well because of ethical 
reasons. All patients were given the opportunity to attend the 
PRISMA program since positive effects were expected. An 
observational study had already shown some improvements 
of PRISMA in self-management behavior (dietary behaviors, 
foot care, and action planning).21
The patients (n=203) with T2DM received either 
PRISMA in addition to usual care or usual care only. The GP 
saw patients once a year to manage their diabetes. In addition 
to these GP visits, every 3–6 months, the PN checked the 
patients’ body weight, blood pressure, and (fasting) blood 
glucose levels. The PNs also inquired about their patients’ 
well-being, hypo- or hyperglycemia, nutrition, exercise, and 
medication, when indicated.
This study was reviewed by the Medical Ethics Com-
mittee of Isala, Zwolle, the Netherlands, which decided that 
according to the Dutch law formal approval was not neces-
sary (METC no 14.07104). The study was conducted in 
accordance with the Declaration of Helsinki, and registered 
at the Dutch Trial Register (no NTR4693). All participants 
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gave written informed consent. All criteria of the CONSORT 
checklist and the minimum criteria of the EMERGE checklist 
were reported. Both checklists are available as supporting 
information (see Checklist S1 and Checklist S2).22,23
Participants
In DESTINE, people 18 years old or older who were diag-
nosed with T2DM and treated in primary care were included. 
The following exclusion criteria were applied by the partici- 
pating GPs: 1) insufficient knowledge of the Dutch language to 
understand the requirements of the study and/or the questions 
posed in the questionnaires, 2) mental retardation, psychiatric 
treatment or schizophrenia, 3) mental disorder bipolar disor-
der, 4) life expectancy less than one year due to malignancies, 
5) and any other serious condition that according to the GPs 
may interfere with trial participation or evaluation results.20
recruitment
GPs (n=8) in the eastern part of the Netherlands participated 
in the study. The GPs selected all eligible patients (see the 
section “Participants”). Eligible patients were then informed 
in detail and recruited by the primary investigator (EdP). 
There was no blinding for the participants, the investigator, 
or the HCP.
intervention
The PRISMA program was offered in addition to usual care. 
The philosophy of PRISMA is based on patient empower-
ment, grounded in the following four psychological models: 
the self-regulation theory,24 the dual process theory,25 the 
self-determination theory,26 and the social learning theory.27 
Although PRISMA was not specifically developed with the 
purpose to increase adherence, it may be improved because it 
is an important aspect of self-management. PRISMA aims to 
empower patients by using a non-didactic learning approach. 
Patients were stimulated to consider their own personal risk 
factors and to choose a specific goal of behavior change, for 
example, “taking a walk every morning,” “quitting smoking,” 
or “taking medication as prescribed.”
The PRISMA program consisted of two meetings of 
3.5 hours each. Groups were guided by a dietician and a PN, 
both experienced in diabetes care. These trainers had fol-
lowed a standardized training program to ensure the quality 
of information delivery.
The first session of the PRISMA program concerned the 
following topics:17 patients’ individual stories, T2DM, the 
effect of insulin or oral blood glucose–lowering medication 
on blood glucose levels, hyper- or hypoglycemia, monitoring 
of blood glucose levels, nutrition (carbohydrates and body 
weight), and in which stage of change the patients consider 
themselves with respect to their nutrition and physical 
activity. The second session concerned a retrospective of 
the first session, complications and personal risk factors, 
nutrition (fat), physical activity, and the patients’ individual 
diabetes action plans.
The participants were stimulated to continue discussing 
their goals and actions with their HCP after completing the 
course. In the intervention group, the participants started 
receiving PRISMA along with usual care (Figure 1). The 
control group participants continued to receive usual care 
and were offered PRISMA after 6 months. Twenty PRISMA 
trainings (which consisted of two meetings each) were con-
ducted to train all the included participants.
randomization
To allocate participants to one of the two groups, non-
stratified block randomization was used. The researcher 
performed the randomization over all general practices in a 
central place were patients’ applications were collected. The 
participants were randomized in ten blocks of 20 participants 
each (ten per arm). The blocks were generated by the order 
of participants’ entry, and each time 20 participants applied, 
who were randomized into two groups. After application, 
patients were matched to a research number which was 
written on a list in order of participants’ entry. The list was 
used to make blocks of 20 participants. Finally, the researcher 
allocated closed, transparent envelopes with a note of the 
patients’ research numbers to one of the groups.
Outcomes
In this analysis, two sources were used to measure adherence: 
1) pharmacy refill data, and 2) self-reported data. The primary 
outcome was adherence based on pharmacy refill data and 
measured using the medication possession ratio (MPR).28 The 
secondary outcomes were the number of times when there 
was a gap of more than 3 days between the theoretical end 
date of the administration period and the dispensing date of 
the next prescription (“drug holidays”), also based on phar-
macy refill data and self-reported adherence, measured by 
the 5-item Medication Adherence Rating Scale (MARS-5).29 
This study focused on the adherence phase, that is, “subop-
timal implementation of the dosing regimen,” for example, 
late, skipped, extra, or reduced doses or drug holidays.
Pharmacy data: MPr
Access to information about the number of dosages dis-
pensed and the dispensing dates was provided by the eleven 
pharmacies where the participants were registered. In the 
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Netherlands, virtually all patients pick up their medication 
at a single pharmacy.30 The medication status and medication 
history of each patient were extracted from the pharmacies’ 
computer information systems.
Adherence to medication was determined using the 
MPR.9 The following three phases describe the process for 
calculating an adherence percentage.
Phase 1: calculate a measuring period
The measuring period started with the first prescription of 
medication before the start of the intervention, or with the first 
medication after the start of the intervention in the case of new 
users. The measuring period ended with the first medication 
prescription 6 months (182 days) after the start of the inter-
vention, or – in the case where no medication was used after 
182 days – with the last available medication prescription.
Phase 2: calculate the MPr
In the measuring period, the number of days for which the 
medication was dispensed was divided by the number of days 
from the first prescription during that period until the end of 
the measurement period. The outcome was expressed as a 
percentage which ranges from 0% to 100%. The higher the 
MPR, the more adherent the patient is.
Phase 3: determine how to handle exceptions
For patients who used more than one medication for their 
T2DM, the adherence for every specific medication was 
measured separately. If patients used two or three medica-
tions simultaneously, the medication with the lowest adher-
ence percentage was analyzed, because the study focused 
on investigating non-adherence. When patients picked up 
their medication too early, multiple prescriptions could 
Inclusion
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Figure 1 Trial design.
Note: The control group also received PrisMA after 6 months (wait-list control).
Abbreviations: PrisMA, Proactive interdisciplinary self-Management; rcT, randomized controlled trial; MPr, medication possession ratio; MArs, Medication Adherence 
rating scale.
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have overlapped. Such overlaps were corrected by the next 
prescription as follows: the overlap of two prescriptions 
was corrected by adding the number of days of overlap in 
the first prescription date and the theoretical end date of the 
second prescription.
Drug holidays and self-reported 
adherence
Dose omissions represented a common form of non-
adherence in patients with T2DM. Therefore, drug holidays 
were a valuable and clinically relevant outcome.31 As men-
tioned earlier, by using the MPR over a period of time, gaps 
could be corrected by overlaps later. However, by adding 
drug holidays as an outcome, it could be detected when 
patients had no medication in stock. The number of drug 
holidays was determined by counting the number of times 
there was a gap of more than 3 days between the theoretical 
end date of the administration period and the dispensing date 
of the next prescription. Whether patients had one or more 
drug holidays (yes/no) was reported, as well as categorized 
into the following: no drug holiday, one drug holiday, and 
two or more drug holidays. To assess self-reported adher-
ence to medication prescriptions, participants were asked to 
complete the MARS-5 questionnaire. This was done at the 
baseline (ie, directly after the PRISMA training), and after 
6 months and 12 months. The MARS-5 consisted of five 
general statements about non-adherent behavior (“I forget to 
take my medicines; I alter the dose of my medicines; I stop 
taking my medicines for a while; I decide to miss a dose; and 
I take less than instructed”) answered on a 5-point Likert scale 
(1= always, 2= often, 3= sometimes, 4= rarely, and 5= never). 
The total MARS-5 score was calculated by summing scores 
from each individual question (range =5–25). Higher scores 
indicate lower self-reported adherence. The level of educa-
tion was also obtained from these questionnaires. The MARS 
has been validated in Dutch.32
Analysis
Pharmacy refill data (MPR) and drug holiday data were avail-
able over a period of 6 and 12 months, and self-reported data 
(MARS) at two points of time: 6 and 12 months. The current 
study distinguished two phases: a randomized controlled 
trial (RCT) phase (0–6 months) and an extension of the RCT 
phase (0–12 months) (Figure 1).
At first, differences between the intervention group and 
the control group were investigated during the RCT phase 
over a period of 6 months, and subsequently, during the 
extension of the RCT phase over a period of 12 months. 
For the RCT phase, an intention to treat (ITT) analysis and 
a per protocol (PP) analysis were conducted. The PP analysis 
included only patients of the intervention group who fol-
lowed PRISMA.
For both the intervention group and the control group, 
the MPR was reported in two categories (yes/no), and the 
drug holidays were reported in two categories (yes/no) and 
in three categories (no drug holiday, one drug holiday, and 
more than one drug holiday). Also, the scores on the five 
items and the average score were calculated (MARS).
statistical methods
Treatment comparisons for efficacy end points were assessed 
with two-sided tests at a significance level of 0.05, includ-
ing a 95% CI. All efficacy analyses were done in the ITT 
population. The analyses in the extension phase comprised all 
patients of the ITT who were randomly assigned in the first 
phase and received PRISMA in the second phase (between 
6 and 12 months). Quantitative variables are described as 
mean and standard deviation, and categorical variables are 
described in numbers and percentages. Independent samples 
t-tests were used to test differences between the groups in 
the case of normally distributed variables; otherwise, the 
Mann–Whitney test was used. The chi-squared tests were 
utilized for categorical data. When PP analyses are done, 
this is stated explicitly. Statistical analyses were conducted 
by using IBM SPSS statistics version 22.
Results
The inclusion period lasted 9 months (June 2014 to February 
2015). Of 1,476 patients, 203 (13.8%) were included in the 
study and signed the informed consent form; 101 patients 
were randomized in the intervention group and 102 in the 
control group. Furthermore, ten patients (4.9%) withdrew 
from the study: six in the intervention group and four in the 
control group. In addition, 31 patients (15.3%) did not use 
blood glucose–lowering medication (n=15 in the interven-
tion group; n=16 in the control group), and for 54 patients 
(26.6%) sufficient pharmacy data were not available (n=24 
in the intervention group; n=30 in the control group). There-
fore, they had no adherence data available and could not be 
included in the analysis. In the intervention group, 46 (82%) 
of 56 patients attended at least one of the two PRISMA meet-
ings. The patient flow chart is presented in Figure 2.
MPr and drug holidays
In the 6-month period, for measuring the MPR and drug 
holidays, 108 (53.2%) of the 203 included patients were 
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
1.
17
4.
24
8.
11
 o
n 
25
-J
un
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2019:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
754
du Pon et al
analyzed for ITT (n=56 in the intervention group; n=52 in the 
control group). In the PP analysis, patients of the intervention 
group who did not attend PRISMA were excluded (n=10). 
Consequently, 98 (90.7%) of the 108 patients were analyzed.
In the 12-month period, for measuring the MPR and drug 
holidays, for the PP analysis, patients (n=16) of the control 
group who did attend PRISMA between 6 and 12 months 
were also excluded. Consequently, 92 (85.2%) of the 
108 patients were analyzed.
MArs
The 6-month MARS questionnaire was completed by 86 
(52.8%) of the 163 patients (n=43 in the intervention group; 
n=43 in the control group). These 86 patients were analyzed 
for ITT. In the PP analysis, patients (n=12) of the interven-
tion group who did not attend PRISMA were excluded. 
Consequently, 74 (86.0%) of the 86 patients were analyzed.
The 12-month MARS questionnaire was completed 
by 68 (41.7%) of the 163 patients. These 68 patients were 
analyzed for ITT. In the PP analysis, patients (n=5) of the 
intervention group who did not attend PRISMA as well as 
patients (n=20) of the control group who did attend PRISMA 
between 6 and 12 months were excluded. Consequently, 
43 patients (63.2%) were analyzed.
Patient characteristics
The patient characteristics are presented in Table 1. Of the 
total sample (n=108), 66.6% were male. The mean age was 
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Figure 2 Patient flowchart.
Note: Patients from the larger trial who did not use blood glucose–lowering medication (n=31) were excluded from this study.
Abbreviations: rcT, randomized controlled trial; MPr, medication possession ratio; MArs, Medication Adherence rating scale.
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69.3 years (SD=9.1), with a minimum age of 50 years and a 
maximum of 87 years.
Table 2 presents the results of the MPR and the number 
of drug holidays for the period of 0–6 months and the scores 
on the items of the MARS at 6 months.
MPr and drug holidays
In the 6-month period, the median MPR was higher in the 
intervention group (100.0) compared to the control group 
(97.7) (U=1,042, z=-2.783, P=0.005 [Table 2]). Also, the 
intervention group was more often completely adherent 
compared to the control group; (X²(1)=8.21, P=0.004). In 
the 6-month period, the relative risk of having one or more 
drug holidays was lower for the intervention group compared 
to the control group (relative risk 0.55, 95% CI, 0.37–0.80).
MArs
The sum scores of the MARS did not differ between the inter-
vention group and the control group: (M=23.98, SD=0.91) 
vs (M=24.00, SD=1.54).
In the 12-month period, the MPR did not differ between 
the groups (U=1,187.5, z=-1.752, P=0.080). Other results did 
not relevantly change in the 12-month period (data not shown).
The results of the PP analysis did not differ from the 
above-mentioned results (data not shown).
Discussion
First, PRISMA resulted in a significantly higher MPR 
in patients with T2DM over a 6-month period. Second, 
PRISMA also resulted in fewer drug holidays. On the other 
hand, self-reported adherence (MARS) did not differ between 
the groups. In the 12-month period, no differences between 
the groups were found in MPR and self-reported adherence.
These results show that PRISMA could be promising for 
improving adherence. Because PRISMA has not specifically 
been developed to improve adherence, the improvements 
could be related to the overall increase of self-management 
behaviors due to PRISMA.17,33 These improvements may 
also be attributed to the medication component discussed 
during PRISMA. PRISMA aims to empower patients. The 
enhanced knowledge about (advantages of taking) blood 
glucose–lowering medication could have stimulated patients 
to take their medication as agreed upon with their HCP. In 
addition, nonspecific effects may play a role, such as increas-
ing patient attention by providing more contact hours with 
HCPs. The lacking effect of the MPR in the 12-month period 
could be explained by the fact that between 6 and 12 months 
both groups received the intervention. In addition, the MPR 
rates were already quite high. Although PRISMA resulted 
in fewer drug holidays, the number of drug holidays was 
already quite low (the ceiling effect).
Table 1 Patient characteristics (n=108)
Characteristics Intervention group (n=56) Control group (n=52)
Male (%) 38 (66.7) 34 (64.2)
Age in categories (years)
50–59
60–69
70–79
$80
 
12 (21.4)
18 (32.1)
21 (37.5)
5 (8.9)
 
6 (11.5)
15 (28.8)
21 (40.4)
10 (19.2)
education level (%)a
low
Moderate
high
Unknown
 
2 (3.6)
26 (46.4)
11 (19.6)
17 (30.4)
 
5 (9.6)
27 (51.9)
6 (11.5)
14 (26.9)
Diabetes duration in years (median, iQr) 6 (4–9) 7 (4–9)
number of blood glucose–lowering medications (%)
One
Two
Three
 
36 (64.3)
18 (32.1)
2 (3.6)
27 (51.9)
24 (46.2)
1 (1.9)
Type of blood glucose–lowering medication(s) (%)
Metformin
gliclazide
Tolbutamide
Other
insulin
53 (94.6)
13 (23.2)
9 (16.1)
4 (7.2)
11 (19.6)
48 (92.3)
18 (34.6)
9 (17.3)
2 (3.8)
14 (26.9)
Notes: alow = no education or primary education; moderate = lower secondary education, (upper) secondary education, or post-secondary non-tertiary education 
(including vocational education); high = tertiary education (bachelor’s degree or higher).
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These results are in line with previous reports of self-
management education programs, which have been shown 
to improve medication adherence in patients with T2DM.12,13 
Tan et al improved medication adherence and the correct 
timing of intake in patients with poorly managed T2DM 
through their structured educational face-to-face program. 
In addition, the pictorial image and teach-back educational 
strategies of Negrabdeh et al seemed to improve medica-
tion adherence among patients with T2DM and low health 
literacy. HCPs often rely on the written word to deal with 
the lack of time to teach patients about self-management. 
However, in the study of Negrabdeh et al, as well as in the 
PRISMA program, simple educational strategies were used, 
such as asking definite questions, avoiding medical jargon, 
encouraging patients to ask questions, and utilizing simple 
pictures with limited content.
Regarding the MARS, the ceiling effect could explain 
why no significant effects were found on the MARS score: 
Patients reported themselves to be very adherent. No patients 
reported stopping taking medicines for a while, and almost no 
patients took less than instructed. According to Van Vught 
et al, primary care patients with T2DM who participated in 
the PRISMA program showed indications of improvement 
in illness perceptions, dietary behaviors, foot care, and 
action planning 3 months after the training.34 In that study, 
no effects on medication adherence were found. However, 
adherence was measured by only one item of the Summary 
of Diabetes Self-Care Activities questionnaire, which is 
of limited reliability. Clearly, the overall increase of self-
management behaviors which the PRISMA program was 
aimed to achieve, combined by the better understanding of the 
ways that “medications” can affect T2DM, was not enough 
to increase the patients’ self-reported adherence.
strengths and limitations
A strength of this study is the multi-measure approach, which 
was used to measure different adherence aspects. There 
are numerous tools available for measuring adherence;34 
nonetheless, currently none of them can be considered the 
gold standard.35,36 Collecting refill data is an objective and 
relatively easy process compared to other methods such as 
pill counts. A main advantage of refill data is that adherence 
rates can be estimated without the patient being aware of it, 
which increases the accuracy of the estimates by eliminating 
any Hawthorne effect.37 In addition, the validated MARS 
questionnaire that was used for self-reported adherence can 
be deployed in any clinical setting and is quick and simple 
because it contains only five questions.29
Some limitations need to be mentioned as well. This 
study focused on the non-adherence phase, that is, suboptimal 
Table 2 results of MPr, drug holidays, and MArs
Adherence outcomes 0–6 months
Intervention group (n=56) Control group (n=52)
MPr
Median (iQr) 100.0 (98.0, 100.0)a 97.7 (94.1, 100.0)
range 51.1–100.0 54.1–100.0
,100 (n, %) 18 (32.1)a 31 (59.6)
100 (n, %) 38 (67.9) 21 (40.4)
Drug holidays
One or more drug holidays (n, %) 14 (25.0) 28 (53.8)
relative risk (95% ci) 0.6 (0.4–0.8)a  
6 months
Intervention group (n=43) Control group (n=43)
MArs (median [range])
item 1: i forget to take medicines 4 (3–5) 4 (3–5)
item 2: i alter the dose of my medicines 5 (3–5) 5 (3–5)
item 3: i stop taking my medicines for a while 5 (4–5) 5 (4–5)
item 4: i decide to miss out a dose 5 (3–5) 5 (3–5)
item 5: i take less than instructed 5 (3–5) 5 (3–5)
sum score 24.0 (0.9) 24.0 (1.5)
Note: aIndicates significance.
Abbreviations: MPr, medication possession ratio; MArs, Medication Adherence rating scale.
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implementation of the dosing regimen. Late or incomplete 
initiation or non-initiation was not applicable, because only 
patients who were already treated by medication for their 
T2DM were included. In addition, early discontinuation 
(non-persistence) could not be detected because the patients’ 
reasons for discontinuation of the treatment were unknown. 
For example, if any drug discontinuation was advised by 
prescriber verbally, without record, this would be missed out.
Despite the strength of using two measures, none of 
them measures true medication intake. The results do not 
absolutely reflect actual patients’ drug intake, because 
patients fill their prescriptions more readily than they take 
their medicine.38 By using electronic medication packaging 
devices, for example, it would be possible to observe each 
single intake and subsequent deviation from the prescribed 
regimen.34 In addition, because the actual medication pickup 
dates were unavailable in the pharmacy’s computer informa-
tion system, the prescription dates were used, which could 
have caused overestimation of adherence. Also, the reliability 
of medication adherence questionnaires is limited.39 Several 
factors could have caused overestimation of the adherence 
rate. The patients in this study reported themselves to be 
very adherent. In general, non-adherent patients do not take 
part voluntarily in studies or do not show up at interventions 
(the healthy worker effect). Moreover, this study measured 
adherence through pharmacy refills, and the measuring 
period only concerns the implementation phase. Further-
more, although self-reporting questionnaires are generally 
considered as the most cost-effective and time-efficient 
way to assess medication adherence, they have also been 
reported to sometimes overestimate adherence.40 It should 
be acknowledged that many patients were lost and could not 
be followed up with for this study. Originally, the patient 
sample was selected from a study20 in which patient selection 
was based on general criteria (people of 18 years and older, 
diagnosed with T2DM) instead of their medication intake 
specifically. Taking blood glucose–lowering medication was 
set as inclusion criteria for the current study. The fact that 
patients who did not use these medications were excluded 
after randomization could have affected the results. The study 
investigated sustainability in the intervention group during 
the 6-month follow-up. This wait-list control design had 
the advantage of creating extra data, while a disadvantage 
was that no effects were expected. In addition, the MARS-5 
questionnaire was completed by the participants after provid-
ing the PRISMA program instead of before. This could have 
been resulted in even more socially desirable answers on the 
MARS-5 questionnaire. Furthermore, despite our efforts to 
enthuse patients about the PRISMA program, only 12% of 
the approached patients participated. The year before the start 
of the study, the PRISMA program was already offered to 
patients treated by several GPs in the Zwolle region, which 
could be an explanation. Patients with an incomplete MARS 
questionnaire were excluded from the analysis because their 
total MARS score was not comparable with the rest of the 
study population. Hence, by excluding them, imputation 
became unnecessary. The large losses to follow-up and the 
low participation rate could have affected the generalizability 
of the study. A disadvantage of these kinds of trials is the 
healthy worker effect, which made the results less generaliz-
able over all T2DM patients in the Netherlands.
Conclusion
Although PRISMA was not specifically developed to increase 
adherence in patients with T2DM, a small improvement 
has still been found in the MPR over a 6-month period. 
PRISMA also resulted in fewer drug holidays over a 6- and 
12-month period. No effects were found in self-reported 
adherence. The adherence rates were quite high already. 
Theoretically based group education such as PRISMA can 
influence health, psychological, and lifestyle outcomes.15,41 
PRISMA was originally developed with the purpose to 
increase self-management behavior in patients with T2DM. 
However, HCPs and policy makers could take into account 
that adherence, as part of diabetes self-management, might be 
influenced by PRISMA. Nowadays, the most recent version 
of PRISMA is extended with education about adherence. 
For future research, it would be of interest to test whether 
this version has a stronger effect on adherence compared to 
the former one.
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